The di-acid metabolite of enalapril, enalaprilat, and its lysine analogue lisinopril are potent
inhibitors of angiotensin converting enzyme (ACE); they do not contain sulphydryl groups …

When three intravenous doses of lisinopril were administered to healthy volunteers, area
under the curve (to infinity) vs dose was linear with a positive intercept. Subtracting area …

Enalapril is administered as the ethyl ester of the potent angiotensin converting enzyme
(ACE) inhibitor enalaprilat. As such, it is 60% absorbed and 40% bioavailable as the active …

Pharmacokinetic and pharmacodynamic variability largely account for interindividual
differences in the response to antihypertensive drugs including angiotensin converting …

The conventional pharmacokinetic profile of the angiotensin converting enzyme (ACE)
inhibitor, enalapril, is a lipid-soluble and relatively inactive prodrug with good oral …

In a randomized, two-period crossover study in 12 normal volunteers, serum and urine
concentrations of the angiotensin-converting enzyme inhibitor enalapril and its active …

Enalapril is a long-acting, sulphydryl-free, ACE inhibitor whose humoral and hypotensive
effects are maximal at 4-8 h and remain detectable at 24 h after a single dose. Serum …

Twelve normal volunteers were given 10 mg enalapril maleate by single and 2 weeks
multiple dose administration, and blood samples were collected for the determination of …

Enalapril clearance after single doses is reduced in the elderly. The influence of age on the
pharmacokinetics and pharmacodynamics of chronic enalapril treatment was examined in …

The pharmacokinetics of angiotension converting enzyme (ACE) inhibitors enalapril (10 mg
orally) and its active metabolite, enalaprilat (10 mg intravenously) were studied in nine …